HDAC9 and meningioma: Furthermore, to enhance therapeutic efficacy, we sought to develop a combination strategy using the HDAC inhibitor Trichostatin A (TSA), which has been associated with the reversal of EMT in several cancers [53, 54] and has been suggested as novel therapeutic approach for meningiomas [55, 56].